文献速递头颈甲状腺与浅表介入US

良性甲状腺结节射频消融后ACR TI-RADS风险评分升高

ACR TI-RADS Risk Score Escalation Observed in Benign Thyroid Nodules following Radiofrequency Ablation.
PubMed 文献 · AJNR Am J Neuroradiol · 2026-04-02

回顾性分析25例患者28个症状性甲状腺结节,射频消融前均行ACR TI-RADS评分和细针穿刺活检,消融后每3个月超声复查并重新评分。中位随访419天,平均体积缩小率66.7%,治疗成功率86%,平均TI-RADS评分从3.04升至4.25(P < .001),主要由低回声和新生强回声灶/钙化驱动;作者指出消融后结构改变导致ACR TI-RADS误导性升级,需谨慎解读。

要点

  • 消融后平均TI-RADS评分从3.04升至4.25(P < .001),主要由低回声和新生强回声灶/钙化驱动。
  • 92.9%结节术前FNA为良性(Bethesda II),治疗成功(VRR >50%)率达86%。
  • 消融后结构改变可致ACR TI-RADS误导性升级,不应作为临床干预依据。

核心结论

  • 甲状腺结节射频消融后常出现结构改变,导致ACR TI-RADS分层系统误导性升级;这些改变属预期表现,需谨慎解读以避免过度诊断、患者焦虑和处理不当。

研究设计与样本

  • 回顾性研究,纳入2021年5月至2024年5月在一家四级学术医疗中心因症状性甲状腺结节接受射频消融的患者,共25例患者28个结节;所有结节治疗前用ACR TI-RADS计算器评估并行细针穿刺活检,消融后每3个月超声复查并重新评估TI-RADS评分;主要终点为消融后TI-RADS分类变化。

关键影像表现/征象

  • 消融后TI-RADS评分升高主要由低回声增加和新生强回声灶/钙化驱动。
  • 平均体积缩小率66.7%(范围33.0%至91.6%),治疗成功(VRR >50%)率86%。

诊断标准与关键数值

  • 采用ACR TI-RADS计算器进行风险分层,消融前平均评分3.04,消融后平均评分4.25(P < .001)。
  • 治疗成功定义为体积缩小率(VRR)>50%,本组86%患者达到。

临床应用与阅片要点

  • 消融后超声复查可见低回声增加和新生强回声灶/钙化,可致ACR TI-RADS评分升高,属预期结构改变。
  • 作者指出这些消融后改变不应作为临床行动的依据,需谨慎解读以避免过度诊断、患者焦虑和处理不当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Radiofrequency ablation (RFA) has emerged as an effective nonsurgical treatment for symptomatic benign thyroid nodules and toxic adenomas. While post-RFA ultrasonographic changes are expected, they may inadvertently evoke alarm and prompt unnecessary interventions when risk stratification models such as the American College of Radiology Thyroid Imaging Reporting & Data System (ACR TI-RADS) are applied. This study aims to quantify ultrasound imaging changes of thyroid nodules using TI-RADS scoring before and after RFA and highlights that these changes should not be used as a basis for clinical action.

MATERIALS AND METHODS: This retrospective study analyzed patients who underwent RFA for symptomatic thyroid nodules at a quaternary care academic medical center between May 2021 and May 2024. All nodules were assessed using the ACR TI-RADS calculator and underwent fine-needle aspiration (FNA) biopsy before treatment. Following RFA, ultrasonography was conducted at 3-month intervals, and TI-RADS scores were reassessed. The primary end point was the change in TI-RADS classification following RFA.

RESULTS: A total of 28 nodules from 25 patients were monitored after RFA for a median follow-up duration of 419 days. Most (92.9%) were benign (Bethesda II) on FNA. The mean volume reduction ratio (VRR) was 66.7% (range 33.0% to 91.6%), with therapeutic success (VRR >50%) achieved in 86% of patients. Post-RFA risk stratification increased following RFA, with the mean TI-RADS score increasing from 3.04 to 4.25 (P < .001), predominantly driven by increased hypoechogenicity and new echogenic foci/calcifications.

CONCLUSIONS: Thyroid nodules frequently undergo post-RFA structural changes that result in misleading upstaging on the ACR TI-RADS stratification system. These changes are expected and require cautious interpretation to avoid overdiagnosis, patient anxiety, and mismanagement.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Battiola TJ, Wiggins RH, Abraham D, et al. ACR TI-RADS Risk Score Escalation Observed in Benign Thyroid Nodules following Radiofrequency Ablation. AJNR Am J Neuroradiol. 2026. PMID: 41027707. doi:10.3174/ajnr.A9028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。